Quetiapine in the treatment of refractory irritable bowel syndrome. A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 715-716

  Martín Blanco, Ana ^a,b   Pascual, Juan C ^a,b   Soler, Joaquim ^a,b   Valdepérez, Ana ^a,b   Pérez, Víctor ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Sta Creu and St Pau Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; LOPERAMIDE; QUETIAPINE; SCOPOLAMINE BROMIDE; TOPIRAMATE; VENLAFAXINE;

ADULT; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; LETTER; MAJOR DEPRESSION; MOOD DISORDER; REMISSION; TREATMENT DURATION;

ADULT; DIBENZOTHIAZEPINES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; TREATMENT OUTCOME;

EID: 77952668443     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.03.014     Document Type: Letter

References (14)

1. Barrachina J., Soler J., Campins M.J., Tejero A., Pascual J.C., Álvarez E., et al. Validation of a Spanish version of the Diagnostic Interview for Borderlines-Revised (DIB-R). Actas Españolas de Psiquiatría 2004, 32(5):293-298.
2. Blankstein U, Chen J, Diamant NE, Davis KD. Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 2010; Jan 4. [Electronic publication ahead of print].
3. Cohrs S., Rodenbeck A., Guan Z., Pohlmann K., Jordan W., Meier A., et al. Sleep promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004, 174:421-429.
4. Creed F., Tomenson B., Guthrie E., Ratcliffe J., Fernandes L., Read N., et al. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. Journal of Psychosomatic Research 2008, 64:613-620.
5. DeVane C.L., Nemeroff C.B. Clinical pharmacokinetics of quetiapine an atypical antipsychotic. Clinical Pharmacokinetics 2001, 40:509-522.
6. Drossman D.A. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. The American Journal of Gastroenterology 2009, 104(12):2897-2902.
7. Drossman D.A., Corazziari E., Delvaux M., Spiller R.C., Talley N.J., Thompson W.G., et al. Rome III: the functional gastrointestinal disorders 2006, Degnon Associates, Inc., McLean, VA. 3rd ed.
8. Fishbain D.A., Cutler R.B., Lewis J., Cole B., Rosomoff R.S., Rosomoff H.L. Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review. Pain Medicine. 2004, 5(4):359-365.
9. Gómez-Beneyto M., Villar M., Renovell M., Pérez F., Hernández M., Leal C., et al. The diagnosis of personality disorder with a modified version of the SCID-II in a Spanish clinical sample. Journal of Personality Disorders 1994, 8:104-110.
10. Grover M., Dorn S.D., Weinland S.R., Dalton C.B., Gaynes B.N., Drossman D.A. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Digestive Diseases and Sciences 2009, 54(6):1284-1291.
11. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone and melperone, preferentially increased dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5HT1a receptor agonism. Brain Research 2002, 956:349-357.
12. Pae C.U., Masand P.S., Ajwani N., Lee C., Patkar A.A. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. International Journal of Clinical Practice 2007, 61(10):1708-1718.
13. Park S.W., Lee S.K., Kim J.M., Yoon J.S., Kim Y.H. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neuroscience Letters 2006, 402(1-2):25-29.
14. Tort S., Balboa A., Marzo M., Carrillo R., Mínguez M., Valdepérez J., et al. Clinical practice guideline for irritable bowel syndrome. Gastroenterol Hepatol 2006, 29(8):467-521.